Highline Capital Management, L.P. Novo Cure LTD Transaction History

Highline Capital Management, L.P.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2018 Nov 14, 2018	SELL	$32.0 - $52.4 $24.8 Million - $40.6 Million	-774,910 Closed	0 $0
Q2 2018 Aug 14, 2018	SELL	$19.85 - $32.0 $5.06 Million - $8.16 Million	-255,000 Reduced 24.76%	774,910 $24.3 Million
Q1 2018 May 15, 2018	SELL	$19.3 - $23.65 $8.58 Million - $10.5 Million	-444,700 Reduced 30.16%	1,029,910 $22.5 Million
Q4 2017 Feb 14, 2018	SELL	$16.3 - $21.9 $642,220 - $862,860	-39,400 Reduced 2.6%	1,474,610 $29.8 Million
Q3 2017 Nov 14, 2017	BUY	$18.05 - $21.75 $27.3 Million - $32.9 Million	1,514,010	1,514,010 $30.1 Million

265

77.1M

751K

293K

Ticker NVCR
Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Shares Outstandng 104,950,000
Market Cap $1.59B
Description
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...

Get notified when there are updates to the investment portfolio of Highline Capital Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Highline Capital Management, L.P. with notifications on news.